Allarity Therapeutics Denmark ApSAktiv
Økonomiske nøgletal
Nøgletal
2025Balancens sammensætning
Selskabsskat
Virksomheden er sambeskattet. Skatten opgøres samlet hos administrationsselskabet Allarity Therapeutics Europe ApS.
Kilde: Skattestyrelsens offentlige skattelister for selskaber. Beregnet skat for indkomståret; kan være lavere end 22 % af indkomsten, fx ved skat betalt i udlandet. sktst.dk
Regnskabstal2017–2025
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|---|
| Balance — aktiver | |||||||||
| Likvide beholdninger | 0 | 49.967 | 8.000 | 124.000 | 821.000 | 4.000 | 4.000 | 4.000 | 4.000 |
| Omsætningsaktiver i alt | 3.239.044 | 218.525 | 2.611.000 | 3.116.000 | 6.935.000 | 6.551.000 | 6.551.000 | 4.000 | 4.000 |
| Anlægsaktiver i alt | 0 | 9.516.044 | 9.516.000 | 9.516.000 | 0 | — | — | — | — |
| Aktiver i alt | 3.239.044 | 9.734.569 | 12.127.000 | 12.632.000 | 6.935.000 | 6.551.000 | 6.551.000 | 4.000 | 4.000 |
| Balance — passiver | |||||||||
| Kortfristede gældsforpligtelser | 3.188.705 | 6.828.824 | 9.647.000 | 12.148.000 | 430.000 | 430.000 | 430.000 | 2.480.000 | 2.480.000 |
| Langfristede gældsforpligtelser | — | — | — | — | 6.423.000 | 7.551.000 | 8.771.000 | 0 | — |
| Gældsforpligtelser i alt | 3.188.705 | 6.828.824 | 9.647.000 | 12.148.000 | 6.853.000 | 7.981.000 | 9.201.000 | 2.480.000 | 2.480.000 |
| Selskabskapital | 50.000 | 100.000 | 100.000 | 100.000 | 100.000 | 100.000 | 100.000 | 100.000 | 100.000 |
| Overført resultat | 339 | -169.555 | -1.408.000 | -3.053.000 | -3.052.000 | -4.505.000 | -5.725.000 | -5.551.000 | -5.551.000 |
| Årets resultat | 339 | -169.894 | -1.238.000 | -1.645.000 | 0 | -1.453.000 | -1.220.000 | 174.000 | 0 |
| Egenkapital i alt | 50.339 | 2.905.745 | 1.667.000 | 22.000 | 23.000 | -1.430.000 | -2.650.000 | -2.476.000 | -2.476.000 |
| Resultatopgørelse | |||||||||
| Bruttofortjeneste | -13.000 | -348.971 | -1.512.000 | -2.169.000 | -1.000 | 0 | — | 33.000 | 0 |
| Resultat af primær drift | — | — | — | — | — | — | — | — | 0 |
| Resultat før skat | 427 | -187.037 | -1.625.000 | -2.238.000 | -7.000 | -1.512.000 | -1.220.000 | — | 0 |
| Årets resultat | 339 | -169.894 | -1.238.000 | -1.645.000 | 0 | -1.453.000 | -1.220.000 | 174.000 | 0 |
| Personaleomkostninger | — | — | — | — | — | — | — | — | — |
| Af- og nedskrivninger | — | — | — | — | — | — | — | — | — |
| Andre nøgletal | |||||||||
| Ansatte | — | — | — | — | 0 | — | — | — | 0 |
En streg (—) betyder, at der ikke er indsendt årsrapport, eller at posten ikke fremgår af den; 0 er et nul angivet i årsrapporten.
Om virksomheden
Årsrapport 2025Business reviewThe Company is a wholly owned subsidiary of Allarity Acquisition Subsidiary, Inc. a Delaware, United States incorporated company; a wholly owned subsidiary of Therapeutics, Inc., a Delaware, United States incorporated Company listed on NASDAQ, in the United States of America. Allarity Therapeutics, Inc. is the ultimate parent company (“Parent Company”) which through its wholly owned subsidiary Allarity Acquisition Subsidiary, Inc., a Delaware, United States incorporated company owns 100% of Allarity Therapeutics Denmark ApS and 100% of Allarity Therapeutics Europe ApS (collectively referred to as the “Group” or the “Allarity Group”. The Company has limited activities.
Financial review The Company's income statement for the year ended 31 December 2025 shows a profit of kDKK 0, and the balance sheet at 31 December 2025 shows negative equity of kDKK 2.476.FinancingSignificant uncertainty as regards going concern The Company has received a letter of support from Allarity Therapeutics Inc. We refer to note 2 for further information. As a result of the Parent Company’s recent financing activities during the first calendar quarter of 2026, the Company issued promissory notes for net proceeds of $20.0 million and implemented a $6.0 million Equity Line of Credit (“ELOC”) based on a S3 shelf registration statement, the current liquidity of the Allarity Group is expected to last through September, 2027. The Company's ability to continue its operations is dependent upon the Allarity Group's current cash and ability to obtain additional capital in the future. The Company’s financial statements for the year ended 31 December 2025 have been prepared on a going concern basis, which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of business for the foreseeable future. These financial statements do not include any adjustments to the specific amounts and classifications of assets and liabilities, which might be necessary should the Company be unable to continue as a going concern.
Uddrag af ledelsesberetningen i den seneste årsrapport.